EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Teva Pharma Industries Ltd (TEVA) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of Teva Pharma Industries Ltd $20.75, price $40.22, upside -48.4%, quality 50 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · US · ADR · ISIN US8816242098

TP Teva Pharma Industries Ltd logo Some data Sep 25, 2026

Teva Pharma Industries Ltd

TEVA · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $20.75 · Strongly overvalued (−48%)
!Quality 50/100
!Weak Growth (revenue 5y +0.7 %/yr)
!Thin margins · 9.0% net margin (TTM)
!High debt · generates free cash flow
!Mixed vs. peers (6/14)
!Moderate moat 53/100
!Insider activity 46/100
!Evidence only medium, so the estimate is less certain
!Weak on future: 12 out of 100
!Weak on balance sheet: 5 out of 100
Watch Teva Pharma Industries Ltd ADR for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$40.22 $6.86 Fair Value $20.75 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 25, 2026.

How to read this chart

60‑month range $6.86 – $40.22 · fair‑value band $10.55 – $31.88 · the $40.22 price screens above the $20.75 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 3 fiscal years are left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 25, 2026.

Follow Teva Pharma Industries Ltd ADR in your weekly email

Every Wednesday you see whether Teva Pharma Industries Ltd ADR is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally.

Show more

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO to treat neurodegenerative and movement disorders " chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv-Yafo, Israel.

Stock analysis

Teva Pharma Industries Ltd ADR (TEVA) currently trades at $40.22, while our model-based Fair Value estimate is $20.75, implying the stock looks roughly 93.8% overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of $24.52 per share, and 0 of the 24 models we run sit above the $40.22 price.

Bear case: the Asset-Based group reads lowest at $4.55, and 24 of the 24 models stay below the price. Evidence for this calculation is medium.

Scenario range: $10.55 (bear) to $31.88 (bull), the price of $40.22 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 50/100 (solid quality), in the Healthcare sector.

Weak Growth: Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.

Teva Pharma Industries Ltd ADR reported revenue of $17.3B in FY2025 versus $15.9B in FY2021, a compound +2.1%/yr. Reported net income was $1.4B in FY2025, compounding +35.6%/yr from FY2021.

Key figures

Market cap $47.2B · P/E ratio 30.0 · P/S ratio 2.45 · EPS (TTM) $1.34 · Net margin 8.2% · Return on equity 21.6% · Return on assets (EBIT) 0.8% · Operating margin 19.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 37 out of 100 (medium confidence).

What moves the price

The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.

The share trades at its 52-week high and 119% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −48%, TEVA screens richer than that median.

Fair Value models

Bear $10.55 Fair Value $20.75 Bull $31.88
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.9839 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF $10.07 $22.42 $41.93 76
Growth DCF $10.29 $20.96 $36.66 75
Owner Earnings $17.77 $34.89 $61.95 73
All 24 models by family
DCF Models
FCF DCF $10.07 $22.42 $41.93 76
Owner Earnings $17.77 $34.89 $61.95 73
5Y Revenue Exit $7.66 $18.43 $32.33 69
5Y EBITDA Exit $13.83 $30.28 $49.88 72
5Y P/E Exit $8.79 $20.61 $33.25 68
10Y Revenue Exit $7.80 $17.97 $32.02 63
10Y EBITDA Exit $12.31 $26.32 $45.75 65
10Y P/E Exit $9.06 $19.51 $32.74 61
Earnings-Based
Graham-Dodd $8.23 $28.96 $38.96 64
Lynch FV $6.76 $9.66 $12.56 61
PEG = 1.0 $6.76 $9.66 $12.56 57
EPV $6.06 $8.71 $11.02 73
Multiples
P/E Multiple $19.98 $26.64 $33.30 63
P/S Multiple $15.44 $20.59 $25.73 58
P/B Multiple $15.44 $20.59 $25.73 55
EV/EBIT $13.80 $21.67 $29.55 64
EV/EBITDA $18.67 $28.16 $37.66 66
EV/Revenue $7.04 $14.27 $21.49 51
Asset-Based
NCAV (Graham) $3.40 $4.55 $6.79 54
Growth DCF
Growth DCF $10.29 $20.96 $36.66 75
Rev-Margin DCF $7.66 $18.41 $31.20 69
Economic Profit
Residual Income $7.93 $10.43 $34.86 58
ROIC Compounder $6.06 $10.08 $15.92 69
Growth Earnings
Growth-Adj P/E $17.17 $24.52 $31.88 67

Open the full fair value analysis →

Notify me when TEVA reaches fair value

Put TEVA on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 50/100

Of which business quality 46 · Market factors (momentum, volatility) 82

Profitability 41
Margins and returns on capital today
Quality Growth 53
Are margins and returns improving?
Cashflow 46
Earnings quality: real cash, not paper profit
Fin. Strength 12
Balance sheet, leverage, solvency risk
Investment 98
Disciplined investing over empire-building
Low Volatility 61
Calm price path (market factor)
Momentum 86
Price trend over the last 3–12 months (market factor)
52W Momentum 100
Distance to the 52-week high (market factor)
Net Issuance 54
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Revenue growth 1 year
+4.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.7%
Start year 2020 (pandemic). Over 10 years: −1.3% a year
Revenue growth 40 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.0%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+26.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+26.1%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.26% vs −4%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−21% → 13%
Start year 2020 (pandemic)
⚠ Revenue per share shrinking 4.7%/yr over ~10Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+25.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+1.9%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +22.4% a year for the price and −0.4% for the forecasts.
Forecast 2026 (sales)−3.5%
Forecast 2027 (sales)+3.7%
Projected 2028 (sales)+3.5%
Projected 2029 (sales)+3.3%
Projected 2030 (sales)+3.0%

TEVA screens 94% overvalued. Compare with Merck KGaA →

Recent news

News mood ⓘNews mood, the average tone of recent news (95 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.

Compare Teva Pharma Industries Ltd ADR with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 629 stocks

Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 50 · Below median
Fair Value upside −48% · Below median
Profitability
Return on equity (TTM) 22% · Top 25%
Return on assets 6% · Top 25%
Net margin (TTM) 9% · Above median
Operating margin (TTM) 19% · Top 25%
Growth and dividend
Revenue growth 2% · Below median
Balance sheet
Debt / equity 1.90× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (TTM) 30.0× · Pricier than median
P/B 5.96× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (TTM) 2.72× · Pricier than median
P/FCF 41.1× · Priciest 25%
EV/EBITDA 11.7× · Cheaper than median
PEG 0.92× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 15
FUTURE (revenue growth)12 · sector 20
PAST (return on equity)86 · sector 27
HEALTH (low debt)5 · sector 96
DIVIDEND (yield)0 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €133.95 €108.70 −19%
Takeda Pharmaceutical Company TAK $18.81 $11.29 −40%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥45.58 ¥50.14 +10%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,865 ₹1,979 +6%
Galderma Group GALD CHF 163.80 CHF 109.88 −33%
Haleon plc HLN $9.25 $8.50 −8%
Sandoz Group SDZ CHF 70.76 CHF 40.16 −43%
Zoetis Inc ZTS $71.61 $108.48 +51%
Hansoh Pharmaceutical Group 3692 HK$35.34 HK$38.87 +10%
United Therapeutics Corporation UTHR $489.42 $793.88 +62%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Teva Pharma Industries Ltd ADR · Fair Value
$20.75 −94%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Teva Pharma Industries Ltd ADR Fair Value". https://www.fairvalue-calculator.com/stock/TEVA

Frequently asked questions

Is Teva Pharma Industries Ltd (TEVA) overvalued or undervalued?
As of Sep 25, 2026, our model estimates a fair value of $20.75 versus a price of $40.22, about −48% upside (overvalued).
What is the fair value of TEVA?
Our model-based fair value for Teva Pharma Industries Ltd ADR is $20.75 (as of Sep 25, 2026), built from audited fundamentals. The current price: $40.22.
What is the quality score of TEVA?
Teva Pharma Industries Ltd ADR has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Teva Pharma Industries Ltd (TEVA)?
Our model-based price target is the fair value of $20.75 (as of Sep 25, 2026) from 24 valuation models. Cautious scenario $10.55, optimistic scenario $31.88. It is a calculation from audited fundamentals, not an analyst target.
What is the Teva Pharma Industries Ltd ADR stock forecast for 2026?
Our models put fair value at $20.75, about −48% upside versus a price of $40.22 (overvalued). Cautious scenario $10.55, optimistic scenario $31.88. The calculation is refreshed regularly with new filings.
What is the revenue of Teva Pharma Industries Ltd (TEVA)?
Teva Pharma Industries Ltd ADR reported trailing-twelve-month revenue of about $17.3B (latest available figure, as of Sep 25, 2026).
What growth is priced into Teva Pharma Industries Ltd (TEVA)?
For today's price to be fair in a discounted-cash-flow model, Teva Pharma Industries Ltd ADR would have to grow free cash flow by +25.3 % per year for five years (discount rate 8.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +0.7 % per year. As of Sep 25, 2026.
What discount rate (WACC) does the fair value of TEVA use?
Our models discount Teva Pharma Industries Ltd ADR at 8.9 %: a base by market capitalisation (large), damped by beta 0.85, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Teva Pharma Industries Ltd ADR that is +25.3 % per year a year over ten years, using the same discount rate (8.9 %) and the same formula as our fair value.
How much growth has Teva Pharma Industries Ltd (TEVA) delivered so far?
Over the past 5 years revenue at Teva Pharma Industries Ltd ADR grew +0.7 % a year. The price currently implies +25.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Teva Pharma Industries Ltd (TEVA) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Teva Pharma Industries Ltd ADR (+25.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Teva Pharma Industries Ltd (TEVA)?
The free-cash-flow yield on the price is 2.43 %: that much free cash flow Teva Pharma Industries Ltd ADR produces per unit of market value. When it exceeds the discount rate of our models (8.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Teva Pharma Industries Ltd (TEVA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Teva Pharma Industries Ltd ADR it is $20.75 per share (as of Sep 25, 2026), against a price of $40.22. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Teva Pharma Industries Ltd ADR stock overvalued or undervalued in 2026?
As of Sep 25, 2026, TEVA trades above its calculated fair value: price $40.22, fair value $20.75, a gap of about −48% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of TEVA?
No. The price is what the market pays today ($40.22); the fair value is what the company's own numbers justify ($20.75). For Teva Pharma Industries Ltd ADR the two are $19.47 per share apart. That gap is exactly why we show both numbers side by side.
How much is Teva Pharma Industries Ltd ADR worth?
The market values Teva Pharma Industries Ltd ADR at about $47.2B (market capitalisation, as of Sep 25, 2026). Per share that is $40.22; our models calculate a fair value of $20.75 per share.
What do the bullish and bearish scenarios say about TEVA?
Our models span a range for Teva Pharma Industries Ltd ADR: cautious scenario $10.55, base $20.75, optimistic $31.88 per share (as of Sep 25, 2026, price $40.22). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of TEVA?
Teva Pharma Industries Ltd ADR trades at a price-to-earnings ratio of 30.0 (as of Sep 25, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $20.75 is built from several models across several years. Other multiples: PEG 0.9, P/B 6.0, P/S 2.7, EV/EBITDA 11.7.
What is the PEG ratio of TEVA?
The PEG ratio of Teva Pharma Industries Ltd ADR is 0.92 (P/E divided by earnings growth, as of Sep 25, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Teva Pharma Industries Ltd (TEVA)?
Balance-sheet figures for Teva Pharma Industries Ltd ADR (as of Sep 25, 2026): return on equity 21.6%, debt of 1.90 per unit of equity. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is TEVA from its 52-week high?
Teva Pharma Industries Ltd ADR trades at $40.22, at its 52-week high of $40.22 and 119% above the low of $18.34 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of $20.75 is for.
Which stocks are comparable to Teva Pharma Industries Ltd ADR?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Teva Pharma Industries Ltd ADR stock attractive at the current price?
The data as of Sep 25, 2026: price $40.22, calculated fair value $20.75 (−48%), Quality Score 50/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of TEVA calculated?
We run Teva Pharma Industries Ltd ADR through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $20.75, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Teva Pharma Industries Ltd ADR itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Teva Pharma Industries Ltd (TEVA)?
The closing price on Sep 24, 2026 was $40.22. Our model-based fair value is $20.75, about −48% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Teva Pharma Industries Ltd ADR right now?
The price sits above even our optimistic bull case ($31.88). The favourable scenario is already priced in. The model range is unusually wide ($10.55 to $31.88). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Teva Pharma Industries Ltd ADR

How large is the market capitalisation of Teva Pharma Industries Ltd (TEVA)?
The market capitalisation of Teva Pharma Industries Ltd ADR is $47.2B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Teva Pharma Industries Ltd (TEVA)?
The price-to-sales ratio of Teva Pharma Industries Ltd ADR is 2.45 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Teva Pharma Industries Ltd (TEVA)?
Earnings per share at Teva Pharma Industries Ltd ADR are $1.34 (price ÷ EPS = P/E 30.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Teva Pharma Industries Ltd (TEVA)?
The net margin of Teva Pharma Industries Ltd ADR is 8.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Teva Pharma Industries Ltd (TEVA)?
The return on equity (ROE) of Teva Pharma Industries Ltd ADR is 21.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Teva Pharma Industries Ltd (TEVA)?
On an EBIT basis the return on assets of Teva Pharma Industries Ltd ADR is 0.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Teva Pharma Industries Ltd (TEVA)?
The operating margin of Teva Pharma Industries Ltd ADR is 19.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Teva Pharma Industries Ltd (TEVA)?
Revenue at Teva Pharma Industries Ltd ADR is growing +2.3% versus a year earlier (3y avg +5.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Teva Pharma Industries Ltd (TEVA)?
Earnings per share at Teva Pharma Industries Ltd ADR are growing +72.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Teva Pharma Industries Ltd (TEVA) carry?
The net debt of Teva Pharma Industries Ltd ADR is $13.8B (fiscal year 2025, ≈ 12.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Teva Pharma Industries Ltd ADR in the live analysis

One click puts Teva Pharma Industries Ltd ADR on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.